Introduction {#s1}
============

Diabetes is referred to a group of diseases characterized by high glucose levels in blood. It is caused by a deficiency in the production or function of insulin or both, which can occur because of different reasons, resulting in protein and lipid metabolic disorders.^[@R1]^ The long-term effects of hypoglycemia are tissue and organ damage.^[@R2]^

Symptoms of diabetes include polyuria, thirst, vision disorders, and weight loss. In some cases there are more severe forms of diabetic ketoacidosis and hyperosmolar that may lead to stupor and coma. But most symptoms are not severe, which may cause damage or even failure of different organs in the long run and lead to irreparable injuries such as blindness, amputation, stroke and eventually death. Previously, type 1 diabetes was called insulin-dependent diabetes and it could happen at any age but is most common in children and young people.^[@R3]^

People with type 1 diabetes are not able to produce enough insulin. This type constitutes about 5%--10% of all cases of diabetes. In this type, the cellular destruction of beta cells occurs in the pancreas. In type 1 diabetes, the pancreas does not release any insulin. Since there is no epidemiologically accurate information on the prevalence and incidence of type 1 diabetes in the world and in the region, therefore, the present study was designed and implemented as a systematic review and meta-analysis, because of geopolitical map of the policy on the prevention and treatment of this disease can be done better.

Materials and Methods {#s2}
=====================

In this systematic review and meta-analysis, a systematic search of resources was conducted by a librarian (N.V.) to investigate the prevalence and incidence of type 1 diabetes (condition) in the people (population) of the world (context). The PICO of study based on the JBI protocol as CoCoPop for prevalence and incidence studies.

Data sources and search strategy {#s2-1}
--------------------------------

The databases of Medline via (PubMed, Ovid), Embase, Scopus, Web of Science from January 1980 to September 2019 were searched to locate English articles. Also, SID, Magiran, and Barakat databases were searched for Persian studies. The grey literature and ongoing studies were searched using the following: OpenGrey, Google Scholar and for thesis and dissertations ProQuest and studies presented at conferences were also searched. Also, experts and professionals on this subject were reached and their opinions were gathered for information on published and unpublished studies. The search was performed using MESH and free keywords. The keywords selected for the search were: "type 1 diabetes", "prevalence", and "incidence" with this search strategy: ((("Diabetes Mellitus, Type 1"\[Mesh\]) OR ((((((((((((((((((((IDDM\[Title/Abstract\]) OR T1DM\[Title/Abstract\]) OR "Type 1 Diabetes"\[Title/Abstract\]) OR "Autoimmune Diabetes"\[Title/Abstract\]) OR "Juvenile Onset Diabetes"\[Title/Abstract\]) OR "Juvenile-Onset Diabetes"\[Title/Abstract\]) OR "Brittle Diabetes Mellitus"\[Title/Abstract\]) OR "brittle diabetes"\[Title/Abstract\]) OR "diabetes mellitus type 1"\[Title/Abstract\]) OR "diabetes mellitus type I"\[Title/Abstract\]) OR "diabetes type 1"\[Title/Abstract\]) OR "diabetes type I"\[Title/Abstract\]) OR "early onset diabetes mellitus"\[Title/Abstract\]) OR "insulin dependent diabetes"\[Title/Abstract\]) OR "juvenile diabetes"\[Title/Abstract\]) OR "juvenile diabetes mellitus"\[Title/Abstract\]) OR "type I diabetes"\[Title/Abstract\]) OR "type I diabetes mellitus"\[Title/Abstract\]) OR "Insulin Dependent Diabetes Mellitus"\[Title/Abstract\]) OR "Insulin-Dependent Diabetes Mellitus"\[Title/Abstract\]))) AND (((("Prevalence"\[Mesh\]) OR ((Prevalence\[Title/Abstract\]) OR Prevalences\[Title/Abstract\]))) OR (("Incidence"\[Mesh\]) OR ((Incidence\[Title/Abstract\]) OR Incidences\[Title/Abstract\]))). The complete search strategy of Medline and Embase is in Supplementary file 1.

Inclusion and exclusion criteria {#s2-2}
--------------------------------

Inclusioncriteria for selecting studies include: 1. Articles published between 1980 and 2019; 2. Articles published in English and Persian. The exclusion criteria were: 1. Studies with no reported sample size; 2. Studies that had low quality; 3. Studies that were published before 1990.

Study selection {#s2-3}
---------------

The located articles were screened in multiple levels of title, abstract, and full-text and final studies that met the inclusion criteria were retrieved and included in the study. The studies were critically appraised by 2 subject specialists and low-quality studies were excluded. In cases of disagreements between two experts (M.M. and M.S.) at each stage of selection and appraisal, third person opinion was used.

Quality appraisal {#s2-4}
-----------------

Articles were evaluated using the STROBE checklist. In this checklist, the minimum score was 2 and the maximum was 4. Finally, articles that received a score of 4 on checklist questions were included in the research, 128 articles earned 4 score, 46 articles earned 3 score and 19 articles earned 2 score and finally their data were extracted to perform the meta-analysis.

Data extraction and quality assessment {#s2-5}
--------------------------------------

The information extracted from the articles were entered in the extraction form. Extracted data included: first author, year of publication, country of study, sample size, and incidence of diabetes in the studies.

Statistical analysis {#s2-6}
--------------------

Statistical analysis was performed using CMA v.2.0 software and *P* value less than 0.05 was considered as significant. The binomial distribution was used to calculate the variance. Weighted mean was used to combine the prevalence rate of different studies. Meta-analysis was used to obtain the incidence of type 1 diabetes. The heterogeneity between studies was assessed by Cochran (Q) and I^[@R2]^ statistics, which expressed the percentage of variation between studies. Random effects model was used to calculate the overall and pooled effect size.

Results {#s3}
=======

Search results and study characteristics {#s3-1}
----------------------------------------

In a systematic search of sources, 65 765 articles were identified. A total of 58 239 articles were duplicates, and 7107 were excluded after reviewing the title and abstract of the articles. After reviewing the full-text articles, 49 articles were excluded. Finally, 193 studies were included in the systematic review and meta-analysis. [Figure 1](#F1){ref-type="fig"} shows the identified and retrieved articles in the study. Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} show the specifications of the articles that were studied.

Figure 1Flow chart of systematic review.

Table 1Characteristics of studies incidence of type 1 diabetes**StudyYearCountryContinentSample sizeIncidence per 10000**Abduljabbar et al^[@R4]^2010Saudi ArabiaAsia10280.02752Abdul-Rasoul et al^[@R5]^2002KuwaitAsia7600.02018Abellana et al^[@R6]^2009SpainEurope4480.0118Ajlouni et al^[@R7]^1999JordanAsia1230.00321070.00281380.0036Alaghehbandan et al^[@R8]^2006CanadaUSA7160.019Alemu et al^[@R9]^2009EthiopiaAfrica810.0021Algert CS et al^[@R10]^2009AustraliaAsia6050.016Altobelli et al^[@R11]^1998ItalyEurope3550.00934Arpi et al^[@R12]^2002CataniaEurope4700.01238Aschner et al^[@R13]^2014AmericaUSA2790.00731Bahíllo et al^[@R14]^2007SpainEurope8350.02222Barat et al^[@R15]^2008FrenchEurope5100.01347Battelino and Kržišnik^[@R16]^1998SloveniaEurope3050.008Berhan et al^[@R17]^2011SwedenEurope16120.0439Bessaoud et al^[@R18]^1990AlgeriaAfrica1680.0044Bizzarri et al^[@R19]^2010ItalyEurope5930.01568Blanchard et al^[@R20]^1997CanadaUSA7680.0204Blumenfeld et al^[@R21]^2014AsiaAsia4330.0114Bratina et al^[@R22]^2001Bosnia and HerzegovinaEurope3250.00854Bruno et al^[@R23]^1990ItalyEurope2590.00678Bruno et al^[@R24]^1993ItalyEurope2560.0067Bruno et al^[@R25]^1997ItalyEurope2820.00739Bruno et al^[@R26]^2001ItalyEurope2970.00778Bruno et al^[@R27]^2009ItalyEurope3540.0093Bruno et al^[@R28]^2010ItalyEurope4650.01226Bruno et al^[@R29]^2013ItalyEurope16440.0448Calle-Pascual et al^[@R30]^1993SpainEurope5650.01493Calori et al^[@R31]^1990ItalyEurope2530.00663Campbell-Stokes and Taylor^[@R32]^2005New ZealandEurope6750.0179Cardwell et al^[@R33]^2006IrelandEurope9250.0247Carrasco et al^[@R34]^1996ChileUSA900.00236Carrasco et al^[@R35]^2006ChileUSA2510.00658Carrasco et al^[@R36]^2006ChileUSA1540.00402Casu et al^[@R37]^2004SardiniaEurope14330.0388Cherubini et al^[@R38]^1994ItalyEurope3090.0081Chong et al^[@R39]^2007AustraliaAsia7310.0194Cinek et al^[@R40]^2000Czech RepublicEurope3840.0101Cinek et al^[@R41]^2003Czech RepublicEurope4440.0117Compés et al^[@R42]^2013SpainEurope7230.0192Cotellessa et al^[@R43]^2003ItalyEurope4760.01256Crow et al^[@R44]^1991EnglandEurope5600.01485080.0134Dabelea et al^[@R45]^2009Navajo nationUSA860.002248410.022414520.03934Dacou-Voutetakis et al^[@R46]^1995GreeceEurope2390.00625Demirbilek et al^[@R47]^2013TurkeyAsia2750.0072Derraik et al^[@R48]^2012New ZealandEurope8450.0225Dziatkowiak et al^[@R49]^2002PolandEurope3160.00832440.00643010.0079Ehehalt et al^[@R50]^2012EuropeEurope5790.0153Ehehalt et al^[@R51]^2009ItalyEurope5600.0148Ehehalt et al^[@R52]^2012EuropeEurope5790.0153El-Ziny et al^[@R53]^2014EgyptAfrica1190.0031Feltbower et al^[@R54]^2002UKEurope4930.013Ferreira et al^[@R55]^1993BrazilUSA2900.0076Forga et al^[@R56]^2013SpainEurope3310.0087Formosa et al^[@R57]^2012MaltaAfrica8210.02186Frazer De Llado et al^[@R58]^1998Puerto RicoUSA6790.018Frongia et al^[@R59]^1997ItalyEurope14110.0382Gardner et al^[@R60]^1997USAUSA7010.0186Charkaluk et al^[@R61]^2002FranceEurope3640.00958Giralt et al^[@R62]^2001SpainEurope9730.026Goday et al^[@R63]^1992SpainEurope4070.0107Gong et al^[@R64]^2013ChinaAsia560.00145Gopinath et al^[@R65]^2008SwedenEurope9140.02438Gorham et al^[@R66]^1993USAUSA8010.0213Grabauskas et al^[@R67]^1991LithuaniaEurope2560.0067Green and Patterson^[@R68]^2001HungaryEurope6860.0182Harjutsalo et al^[@R69]^2008FinlandEurope15770.0429Harjutsalo et al^[@R70]^2013FinlandEurope22640.0629Huen et al^[@R71]^2000Hong KongAsia540.0014Jarosz-Chobot et al^[@R72]^2010PolandEurope3750.00987Jarosz-Chobot et al^[@R73]^2011PolandEurope3880.0102Ji et al^[@R74]^2010SwedenEurope270.00071Kadiki and Moawad^[@R75]^1994LibyaAfrica3350.0088Kadiki et al^[@R76]^1996LibyaAfrica3430.009Karvonen et al^[@R77]^1996FinlandEurope13190.0356Karvonen et al^[@R78]^2000China & VenezuelaAsia40.0001Karvonen et al^[@R79]^1997FinlandEurope15070.0409Kida et al^[@R80]^1999JapanAsia580.0015Koton^[@R81]^2007AsiaAsia3050.008Kulaylat and Narchi^[@R82]^2000Saudi ArabiaAsia4370.0115Lammi et al^[@R83]^2007FinlandEurope6010.0159Larenas et al^[@R84]^1996ChileUSA490.00127Lawrence et al^[@R85]^2014USAUSA9140.0244Legault and Polychronakos^[@R86]^2006CanadaUSA5680.015Libman et al^[@R87]^1998USAUSA6310.0167Lin et al^[@R88]^2014TaiwanAsia1280.00334Lipman^[@R89]^1993USAUSA4940.01302Lipman et al^[@R90]^2002USAUSA5040.0133Lipman et al^[@R91]^2006USAUSA5600.0148Lipman et al^[@R92]^2013USAUSA6420.017Lipton et al^[@R93]^2002USAUSA5750.0152Lisbôa et al^[@R94]^1998BrazilUSA4550.012Li et al^[@R95]^2000ChinaAsia220.00056Lora-Gómez et al^[@R96]^2005SpainEurope6350.0168Mamoulakis et al^[@R97]^2003CreteEurope2330.0061Martinucci et al^[@R98]^2002BelarusEurope1760.0046Mauny et al^[@R99]^2005FranceEurope2300.00603Mayer-Davis et al^[@R100]^2009USAUSA5940.0157Mazzella et al^[@R101]^1994ItalyEurope4450.01172Metcalfe and Baum^[@R102]^1991BritainEurope5120.0135Michalková et al^[@R103]^2004SlovakiaEurope5290.01396Morales-Pérez et al^[@R104]^2000SpainEurope4850.0128Muiña et al^[@R105]^2012SpainEurope10310.0276Muntoni et al^[@R106]^1992SardiniaEurope9110.0243Muntoni et al^[@R107]^1997ItalyEurope12550.0338Neu et al^[@R108]^1997GermanEurope4400.0116Neu et al^[@R109]^2001EuropeEurope4740.0125Newhook et al^[@R110]^2004CanadaUSA13310.03593Newhook et al^[@R111]^2008CanadaUSA13000.03508Newhook et al^[@R112]^2012CanadaUSA13940.0377Ostrauskas et al^[@R113]^2011LithuaniaEurope3160.0083Patterson et al^[@R114]^2000MacedoniaEurope1230.0032Patterson et al^[@R115]^2001FinlandEurope14820.0402Peter^[@R116]^2007BahamasUSA3840.0101Pinelli et al^[@R117]^1998ItalyEurope4070.0107Pishdad^[@R118]^2005IranAsia1200.00314Podar et al^[@R119]^1992EstoniaEurope4480.0118Polanska et al^[@R120]^2014PolandEurope4520.01192Prisco et al^[@R121]^1996ItalyEurope2320.00607Pronina et al^[@R122]^2008MoscowEurope4890.0129Pundziute-Lyckå et al^[@R123]^2003LithuaniaEurope3610.00952630.0069Radosevic et al^[@R124]^2013Bosnia and HerzegovinaEurope2860.0075Slovenia4740.0125Ramachandran et al^[@R125]^1996IndiaAsia3990.0105Rami et al^[@R126]^2001AustriaAsia3420.00899Rangasami et al^[@R127]^1997ScotlandEurope8960.0239Serrano Río et al^[@R128]^1990SpainEurope4290.0113Roche et al^[@R129]^2002IrelandEurope6270.0166Rosenbauer et al^[@R130]^1999EuropeEurope3090.0081Aude Rueda et al^[@R131]^1998MexicoUSA440.00115Rytkönen et al^[@R132]^2003FinlandEurope13830.0374Samardzic et al^[@R133]^2010MontenegroEurope5080.0134Samuelsson et al^[@R134]^1994SwedenEurope9440.0252Santos et al^[@R135]^2001ChileUSA1570.00411Sasaki and Okamoto^[@R136]^1992JapanAsia640.00168770.002Schober et al^[@R137]^1995AustraliaAsia3010.0079Schober et al^[@R138]^2009AustriaAsia6940.0184Schoenle et al^[@R139]^2001SwitzerlandEurope3990.0105Scott et al^[@R140]^1992New ZealandEurope4820.0127Sebastiani et al^[@R141]^1996ItalyEurope3010.0079Sella et al^[@R142]^2010AsiaAsia4810.01269Sereday et al^[@R143]^1994ArgentinaUSA26940.0759Shaltout et al^[@R144]^2002KuwaitAsia7570.0201Shamis et al^[@R145]^1997AsiaAsia2780.0073López Siguero et al^[@R146]^1997MalagaEurope5410.0143Sipetic et al^[@R147]^2013SerbiaEurope3950.0104Skordis and Hadjiloizou^[@R148]^1997GreeceEurope3990.0105Skordis et al^[@R149]^2002GreeceEurope4300.01132Skordis et al^[@R150]^2012CyprusAsia4730.01246Skrivarhaug et al^[@R151]^2014NorwayEurope12150.0327Smith et al^[@R152]^2007USAUSA6830.0181Staines et al^[@R153]^1993UKEurope5190.0137Staines et al^[@R154]^1997PakistanAsia390.00102Stipancic et al^[@R155]^2008CroatiaEurope3380.00887Svensson et al^[@R156]^2002DenmarkEurope7310.0194Svensson et al^[@R157]^2008DenmarkEurope8270.022Swai et al^[@R158]^1993TanzaniaAfrica580.0015Tahirovic et al^[@R159]^2007Bosnia and HerzegovinaEurope2710.0071Taplin et al^[@R160]^2005New South WalesAsia7860.0209Teeäär et al^[@R161]^2009EstoniaEurope6490.0172Thunander et al^[@R162]^2008SwedenEurope13970.0378Torffvit et al^[@R163]^2007SwedenEurope4820.0127Toth et al^[@R164]^1997CanadaUSA9620.0257Toumba et al^[@R165]^2007CyprusAsia4520.0119Tran et al^[@R166]^2014AustraliaAsia8270.022Tuchinda et al^[@R167]^2002ThailandAsia630.00165Tull et al^[@R168]^1991Virgin IslandsUSA2860.0075Tuomilehto et al^[@R169]^1991FinlandEurope12190.0328Tuomilehto-Wolf et al^[@R170]^1991EstoniaEurope4070.0107Tuomilehto et al^[@R171]^1992FinlandEurope13050.0352Tuomilehto et al^[@R172]^1992FinlandEurope10310.0276Tuomilehto et al^[@R173]^1993MauritiusAfrica810.0021Tuomilehto et al^[@R174]^199FinlandEurope13690.037Tzaneva et al^[@R175]^1998BulgariaEurope2410.00632Vandewalle et al^[@R176]^1997BelgiumEurope4480.0118Vehik^[@R177]^2007ColoradoUSA5600.0148Verge et al^[@R178]^1994AustraliaAsia5490.0145Vichi et al^[@R179]^2014ItalyEurope5080.0134Vlajinac et al^[@R180]^1995SerbiaEurope2940.0077Vos et al^[@R181]^1996NetherlandEurope7530.02Wadsworth et al^[@R182]^1995EnglandEurope3540.0093Washington et al^[@R183]^2012USAVirgin IslandsUSA5790.0153Willis et al^[@R184]^2002New ZealandEurope7570.02012Wong^[@R185]^1994ChinaAsia650.0017Wong et al^[@R186]^1993Hong KongAsia770.002Yang et al^[@R187]^1998ChinaAsia180.00048Yang et al^[@R188]^2005ChinaAsia180.00047Zalutskaya et al^[@R189]^2004Gomel areaEurope3000.00786Minsk area1270.00332Zhao et al^[@R190]^1999EnglandEurope5640.0149Zhao et al^[@R191]^2014ChinaChina1190.0031Zubkiewicz-Kucharska and Noczyńska^[@R192]^2010PolandEurope4710.01241

Table 2Prevalence and incidence of type 1 diabetes in the world**Prevalence Per 10 000Incidence Per 100 000**World5.915Asia9.615Africa5.38Europe2.12America3.920

Table 3Characteristics of studies prevalence of type 1 diabetes**StudyCountrySample SizePrevalence Per 100 000**Akazawa^[@R193]^Japan4010Akesen et al^[@R194]^Turkey2667Al-Herbish et al^[@R195]^Saudi Arabia42109.5Aschner et al^[@R13]^America28278000Bessaoud et al^[@R18]^Algeria1027Dabelea et al^[@R45]^Navajo nation40113181106278Dabelea et al^[@R196]^USA57148Ehehalt et al^[@R51]^Italy376111000Elamin et al^[@R197]^Sudan1742.98El-Ziny et al^[@R53]^Egypt1026.8Eriksson et al^[@R198]^Finland10092700Evans et al^[@R199]^Scotland659222000Frongia et al^[@R59]^Italy176459Garancini et al^[@R200]^Italy3180Gujral et al^[@R201]^UK2975Jorge et al^[@R202]^Portugal49128Kemper et al^[@R203]^USA70183Mayer-Davis et al^[@R100]^USA218570Moussa et al^[@R204]^Kuwait103269.9Ostrauskas^[@R205]^Lithuania3180.64Ostrauskas and Žalinkevičius^[@R206]^Lithuania2770.23Peter et al^[@R116]^Bahamas1231Pettitt et al^[@R207]^USA74193Ramachandran et al^[@R208]^India1026Rangasami et al^[@R127]^Scotland58150Scott et al^[@R140]^New Zealand44115López Siguero et al^[@R146]^Malaga297780Soliman et al^[@R209]^Oman5013.25Songini et al^[@R210]^Sardinia46119Wong^[@R185]^China308.3Wu et al^[@R211]^New Zealand87227

Prevalence and incidence of type 1 diabetes in Asia {#s3-2}
---------------------------------------------------

Prevalence and incidence of type 1 diabetes were extracted from meta-analysis studies. In type 1 diabetes incidence, the heterogeneity between studies in the meta-analysis was significant (Q = 50.51; df = 16; *P* \< 0.001; I^2^ = 68.33), but in the prevalence of diabetes 1, the heterogeneity was not significant (Q = 5220; *df* = 6; *P* \< 0.001; I^2^ = 99.88). The incidence of type 1 diabetes in Asia was 15 per 100 000 population, which was statistically significant (Incidence = 0.015, 95% CI = 0.010 to 0.021, *P* \< 0.001), and the prevalence of type 1 diabetes was 6.9 per 10 000 people, which was statistically significant (Prevalence = 0.069, 95% CI = 0.020 to 0.214, *P* \< 0.001). [Figures 2A and 2B](#F2){ref-type="fig"} show the forest plot of prevalence and incidence of type 1 diabetes in Asia.

Figure 2(A) Incidence and (B) prevalence of type 1 diabetes in Asia.

Prevalence and incidence of type 1 diabetes in Africa {#s3-3}
-----------------------------------------------------

Prevalence and incidence of type 1 diabetes were extracted from meta-analysis studies. In type 1 diabetes incidence, the heterogeneity between studies in the meta-analysis was not significant (Q = 23.79; *df* = 6; *P* \< 0.001; I^2^ = 74.78) and in the prevalence of diabetes 1, the heterogeneity was not significant too, (Q = 4.4; *df* = 1; *P* \< 0.001; I^2^ = 77.27). The incidence of type 1 diabetes in Africa was 8 per 100 000 population, which was statistically significant (Incidence = 0.008, 95% CI = 0.003 to 0.021 *P* \< 0.001), and the prevalence of type 1 diabetes was 3.5 per 10 000 people, which was not statistically significant (prevalence = 0.035, 95% CI: 0.022 to 0.055, *P* \< 0.001). [Figures 3A and 3B](#F3){ref-type="fig"} show the forest plot of prevalence and incidence of type 1 diabetes in Africa.

Figure 3(A) Incidence and (B) prevalence of type 1 diabetes in Africa.

Prevalence and incidence of type 1 diabetes in Europe {#s3-4}
-----------------------------------------------------

Prevalence and incidence of type 1 diabetes were extracted from meta-analysis studies. In type 1 diabetes incidence, the heterogeneity between studies in the meta-analysis was significant (Q = 895.56, *df* = 96, *P* \< 0.001, I^2^ = 89.28) but in the prevalence of diabetes 1, the heterogeneity was not significant, (Q = 5792.85, *df* = 15, *P* \< 0.001, I^2^ = 99.74). The incidence of type 1 diabetes in Europe was 15 per 100 000 population, which was statistically significant (Incidence = 0.015, 95% CI = 0.013 to 0.018, *P* \< 0.001), and the prevalence of type 1 diabetes was 12.2 per 10 000 people, which was statistically significant (Prevalence = 0.122, 95% CI = 0.085 to 0.171, *P* \< 0.001). [Figures 4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"} show the forest plot of prevalence and incidence of type 1 diabetes in Europe.

Figure 4Incidence of type 1 diabetes in Europe.

Figure 5Prevalence of type 1 diabetes in Europe.

Prevalence and incidence of type 1 diabetes in America {#s3-5}
------------------------------------------------------

Prevalence and incidence of type 1 diabetes were extracted from meta-analysis studies. In type 1 diabetes incidence, the heterogeneity between studies in the meta-analysis was significant (Q = 18.88, *df* = 16, *P* = 0.27, I^2^ = 15.28) and in the prevalence of diabetes 1, the heterogeneity was significant too, (Q = 1120.79, df = 7, *P* \< 0.001, I^2^ = 99.38). The incidence of type 1 diabetes in America was 20 per 100 000 population, which was statistically significant (Incidence = 0.020, 95% CI = 0.010 to 0.021, *P* \< 0.001), and the prevalence of type 1 diabetes was 12.2 per 10 000 people, which was statistically significant (Prevalence = 0.093, 95% CI = 0.063 to 0.137, *P* \< 0.001). [Figures 6A and 6B](#F6){ref-type="fig"} show the forest plot of prevalence and incidence of type 1 diabetes in America. A sensitivity analysis was done for Incidence of type 1 diabetes in America based on excluding studies with too wide CIs. Sensitivity analysis's results show that the incidence of type 1 diabetes in America is 19 per 100 000 population, which is statistically significant (Incidence = 0.019, 95% CI = 0.016 to 0.022, *P* \< 0.001).

Figure 6(A) Incidence and (B) prevalence of type 1 diabetes in America.

Prevalence and incidence of type 1 diabetes in the world {#s3-6}
--------------------------------------------------------

Prevalence and incidence of type 1 diabetes were extracted from meta-analysis studies. In type 1 diabetes incidence, the heterogeneity between studies in the meta-analysis was significant (Q = 1020.30, df = 137, *P* \< 0.001, I^2^ = 86.57) and in the prevalence of diabetes 1, the heterogeneity was significant too, (Q = 14760.32, df = 32, *P* \< 0.001, I^2^ = 99.78). The incidence of type 1 diabetes in world was 15 per 100 000 population, which was statistically significant (Incidence = 0.015, 95% CI = 0.013 to 0.017, *P* \< 0.001), and the prevalence of type 1 diabetes was 9.5 per 10 000 people, which was statistically significant (prevalence = 0.095, 95% CI = 0.070 to 0.128, *P* \< 0.001). [Figure 7](#F7){ref-type="fig"} shows the forest plot of prevalence and incidence of type 1 diabetes in the world.

Figure 7Prevalence of type 1 diabetes in the world.

Publication bias {#s3-7}
----------------

In order to assess the publication bias, Eggers Regression test was used. Based on the results, the population bias between studies was not significant (t-value = 1.26, *df* 93, *P* = 0.21).

Meta-Regression {#s3-8}
---------------

Meta-regression was used to determine the effect of time on type 1 diabetes incidence. The results showed that the incidence of type 1 diabetes has increased over time. The meta-regression plot is shown in [Figure 8](#F8){ref-type="fig"}.

Figure 8The meta-regression plot.

Discussion {#s4}
==========

The global trend of increasing prevalence of type 1 diabetes, with multiple etiologies, operates through multiple mechanisms. In the present study, data were extracted from 193 articles between 1990 and 2019. The results showed that the incidence of type 1 diabetes in continental subgroups (Asia, Africa, Europe, and America) was 15 per 100 000, 8 per 100 000, 15 per 100 000 and 20 per 100, respectively. Also, the global prevalence of continental subtypes of type 1 diabetes in the above regions was, 6.9 per 10 000, 3.5 per 10 000, and 12.2 per 10 000, respectively.

Relative differences between obtained results and previous statistics may be due to different research time periods and new global population status. Especially in recent years (social, political and economic migration), the changing global climate coupled with new policies and sanctions that have led to poorer middle-income and low-income countries.^[@R212]^

The pathogenesis of type 2 diabetes is known, which is associated with different genes and the involvement of multiple factors. Type 2 diabetes can be prevented and treated by removing or reducing these factors. Most of the warnings of national and international health bodies and diabetes associations are based on lifestyle changes and stress reduction that can prevent diabetes.^[@R213]^

But in type 1 diabetes, that make up 5 to 15 percent of diabetics and often involve children, Prevention ways have not yet been defined. However, screening of type 1 diabetes in prone families in relation to autoantibodies has recently been proposed. Also, clinical studies on the prevention of type 1 diabetes have been conducted.^[@R214]^

If one foot was amputated every 30 seconds, today it's every 15 seconds. Need for dialysis equipment will increase. The CCU and ICU beds will be full of stroke and myocardial infarction patients. The population of the blind increases and unfortunately, new, effective, and less complicated treatments become more expensive.^[@R215]^

The disease shows a significant increase in glucose and possibly DKA. These patients definitely need insulin due to the pathogenesis of insulin deficiency. Manufacturing and production of insulin (traditional insulins and analog insulins) and insulin pumps, despite being inexpensive in producing countries, is shipped to low- and middle-income countries for high prices which is a major problem for the managing of type 1 diabetes patients. Certainly, uncontrolled hyperglycemia in type 1 diabetic patients will make all the problems more severe.^[@R216]^

Limitations {#s4-1}
-----------

One of the limitations of the study was the poor quality of some articles and, despite a careful search, the lack of access to some of the full text of the published articles.

Conclusion {#s5}
==========

According to the results, the incidence and prevalence of type 1 diabetes are increasing in the world. As a result, insulin will be difficult to access and afford, especially in underdeveloped and developing countries. Thus, warnings about this can help international organizations and countries to plan for preventive measures.
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